The story of Sildenafil presents a interesting case for stakeholders in the pharmaceutical sector. While initially a tremendous success, producing vast sums, the exclusivity lapse and the subsequent flood of generic competitors have drastically affected revenue. This raises questions about the long-term profitability of similar medication innovatio